Ultragenyx Pharmaceutical (RARE) said Thursday it submitted a biologics license application to the US Food and Drug Administration for accelerated approval for UX111 to treat Sanfilippo syndrome type A, a lysosomal storage disease that mainly affects the brain.
The company said the submission is supported by available data, including from a study that showed "rapid and sustained decreased levels" of heparan sulfate in cerebral spinal fluid in patients treated with UX111.
Ultragenyx shares were down 1.9% in recent trading.
Price: 42.30, Change: -0.64, Percent Change: -1.49
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.